Latest News

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performanc...

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Rev...

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results De...

Teva Statement on European Commission Decision; Company to Appeal

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab...

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA